Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01207388 · OUTCOME

Overall Survival

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) · Source last updated 2020-02-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.

What was measured

Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.

Analysis population: Full analysis set

Groups in this outcome

Blinatumomab

Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Blinatumomab116

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Blinatumomab36.5Not reported19.2NANot estimable at the time of analysis due to the low number of events
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Not estimable at the time of analysis due to the low number of events
        group Id
        OG000
        lower Limit
        19.2
        upper Limit
        NA
        value
        36.5
denoms
  1. counts
    1. group Id
      OG000
      value
      116
    units
    Participants
description
Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.
    id
    OG000
    title
    Blinatumomab
param Type
MEDIAN
population Description
Full analysis set
reporting Status
POSTED
time Frame
Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.
title
Overall Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice